Botanix Pharmaceuticals (ASX:BOT) Stock Price Down 2%
Shares of Botanix Pharmaceuticals Ltd (ASX:BOT) fell 2% during trading on Tuesday . The stock traded as low as A$0.24 ($0.17) and last traded at A$0.25 ($0.18), 2,207,570 shares changed hands during mid-day trading. A decline of 50% from the average session volume of 4,450,000 shares. The stock had previously closed at A$0.26 ($0.18).
The firm has a market cap of $250.77 million and a P/E ratio of -11.36. The firm’s 50-day simple moving average is A$0.24 and its 200 day simple moving average is A$0.15.
In related news, insider Michael Thurn 5,000,000 shares of the stock in a transaction dated Thursday, July 18th.
Botanix Pharmaceuticals Limited, a clinical stage medical dermatology company, develops therapeutics for the treatment of serious skin diseases in Australia. The company offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1308, a transdermal gel formulation for the treatment of plaque psoriasis; BTX 1204, a transdermal gel formation for the treatment of atopic dermatitis; and BTX 1701, a novel product for mild acne.
Featured Story: Google Finance
Receive News & Ratings for Botanix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Botanix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.